Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
via Google News
The Latest on: Cancer
- Rep. Watson Coleman: I’m 75. I had cancer. I got covid-19 because my GOP colleagues dismiss facts.on January 12, 2021 at 5:24 pm
Bonnie Watson Coleman, a Democrat, represents New Jersey’s 12th Congressional District in the U.S. House of Representatives. Over the past day, a lot of people have asked me how I feel. They are ...
- J&J Opposes Former Talc Supplier’s Bankruptcy Plan to Resolve Cancer Claimson January 12, 2021 at 5:05 pm
Imerys SA is pressing ahead in an effort to get out from under lawsuits over its U.S. mining operation, Imerys Talc America, over the protests of Johnson & Johnson.
- Cancer Death Rate in U.S. Falls by Largest Yearly Amount on Recordon January 12, 2021 at 4:28 pm
New lung-cancer treatments helped propel overall declines in recent years, the American Cancer Society said.
- Cancer deaths in U.S. down by nearly one-third in last 20 years, analysis findson January 12, 2021 at 2:30 pm
Deaths from cancer in the United States fell 31% between 1991 and 2018, including a 2.4% decline from 2017 to 2018, according to an analysis published Tuesday by the American Cancer Society.
- Sanofi, Israel's Biond Biologics to collaborate on new cancer drugon January 12, 2021 at 10:31 am
Israel's Biond Biologics Ltd said on Tuesday it had forged an exclusive global licence agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and ...
- Record Drop In Cancer Mortality Reported For Second Straight Yearon January 12, 2021 at 8:27 am
The drop is underpinned by significant progress in lung cancer treatment, although it still remains the #1 cause of death from cancer.
- Cancer deaths down for 2nd year in a row, but impact of COVID remains unknownon January 12, 2021 at 8:22 am
Cancer is one of the most important health challenges our nation faces and the second leading cause of death in the United States. Now, a new study from the American Cancer Society finds that the rate ...
- Another record decline reported in US cancer death rateon January 12, 2021 at 7:24 am
Researchers on Tuesday reported another record one-year decline in the U.S. cancer death rate, a drop they attribute to success against lung cancer. The overall cancer death rate has been falling ...
- How Our Sex Habits May Affect Our HPV and Cancer Riskon January 12, 2021 at 6:48 am
Certain sex practices, at certain ages, increased the risk of throat cancers related to human papillomavirus. By Nicholas Bakalar Human papillomavirus, or HPV, is a leading cause of throat cancer, and ...
- Parasite found in cat poop linked to higher brain cancer risk in humanson January 12, 2021 at 4:00 am
Exposure to Toxoplasma gondii, which reproduces in cats and most often spreads to humans through raw meat, may increase the risk of brain cancer.
via Bing News